How this fund's holdings score on the six lenses, weighted by holding weight — plus what the manager is actively buying and selling. A transparency roll-up of the stock atom — descriptive, not a forecast of outperformance.
What's a “leader”? A holding that ranks in the top two deciles (D9 / D10) of its size cohort on BOTH active conviction lenses — Technical and Flow. Leadership-breadth is the share of the fund's weight sitting in those leaders.
Risk & return
Compound returns and the risk taken to earn them, from the fund's own NAV history.
| Sector | 11 Jul | 18 Jul | 25 Jul | 24 Aug | 28 Aug | 04 Sep | Δ |
|---|---|---|---|---|---|---|---|
| Pharma | 51.3 | 50.5 | 50.5 | 54.8 | 54.8 | 54.8 | +3.4 |
| Healthcare | 23.0 | 24.4 | 24.4 | 25.2 | 25.2 | 25.2 | +2.2 |
| Unclassified | · | · | · | 3.0 | 3.0 | 3.0 | 0.0 |
| Financial Services | 1.3 | 1.2 | 1.2 | 1.1 | 1.1 | 1.1 | -0.2 |
Glass box
Click a lens to expand its holdings, ranked by contribution (weight × decile); each name links to its own evidence. Descriptive, not a forecast.
—
—
| Symbol | Sector | Weight | Tch | Fnd | Cat | Flw | Val | Lead | RS 3M |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | Pharma | 8.40% | 7 | 8 | 7 | 8 | 5 | — | +1.5% |
| IPCALAB | Pharma | 8.15% | 9 | 5 | 1 | 3 | 4 | — | +14.3% |
| CIPLA | Pharma | 8.10% | 4 | 3 | 6 | 4 | 7 | — | -3.9% |
| SAILIFE | Healthcare | 7.07% | 9 | 10 | 5 | 9 | 1 | Leader | +27.8% |
| GLAND | Pharma | 6.33% | 10 | 7 | 5 | 4 | 4 | Leader | +27.9% |
| APOLLOHOSP | Healthcare | 5.79% | 9 | 5 | 5 | 2 | 2 | — | +0.4% |
| ALKEM | Pharma | 4.64% | 3 | 8 | 7 | 6 | 8 | — | -6.6% |
| COHANCE | Healthcare | 3.74% | 4 | 5 | 6 | 3 | 5 | — | +1.5% |
| VIJAYA | Pharma | 3.46% | 7 | 10 | 5 | 4 | 1 | — | +10.1% |
| APLLTD | Pharma | 3.16% | 4 | 5 | 10 | 2 | 9 | — | +2.8% |
| PGHL | Pharma | 2.89% | 4 | 4 | 1 | 8 | 5 | — | -13.0% |
| PFIZER | Healthcare | 2.73% | 5 | 7 | 1 | 8 | 7 | — | -2.9% |
| DIVISLAB | Pharma | 2.33% | 9 | 8 | 1 | 4 | 1 | — | +38.4% |
| INDOCO | Pharma | 1.96% | 10 | 2 | 4 | 6 | 6 | Leader | +21.2% |
| CONCORDBIO | Pharma | 1.94% | 8 | 4 | 2 | 5 | 3 | — | +16.2% |
| UNICHEMLAB | Pharma | 1.59% | 10 | 7 | 2 | 10 | 7 | Leader | +55.2% |
| SYNGENE | Healthcare | 1.33% | 1 | 2 | 6 | 7 | 7 | — | -17.8% |
| NEPHROPLUS | Healthcare | 1.19% | 6 | 5 | 6 | 5 | 9 | — | +2.5% |
| ICICIGI | Financial Services | 1.08% | 1 | 6 | 4 | 6 | 8 | — | -18.5% |
| AARTIDRUGS | Pharma | 0.99% | 9 | 4 | 6 | 7 | 7 | — | +11.1% |
| ERIS | Pharma | 0.84% | 3 | 8 | 4 | 9 | 8 | — | -7.4% |
| JLHL | Healthcare | 0.47% | 1 | 9 | 4 | 2 | 10 | — | -83.0% |
Performance · 5.0y
Over the last 5.0 years ₹100 in the fund grew to ₹192 (+92%), vs ₹156 for Nifty 500 (+56%) and ₹137 for Nifty 50 (+37%). Its relative-strength line ended at 140 vs Nifty 50 and 123 vs Nifty 500 — above 100, sustained outperformance.